GlobeNewswire

Appian Helps University of Wollongong Streamline the International Student Journey

Dela

The Appian platform automates and digitises study abroad and exchange applications

RESTON, Va. and SYDNEY, Australia, May 30, 2018 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN), a leading Low-Code and Business Process Management platform provider, today announced the University of Wollongong (UOW) has selected Appian to automate and digitise the application journey for its international students.

UOW's new International On-line Student Mobility Application helps streamline application processes for international students wanting to study abroad, undertake an exchange or take part in the Visiting Research Program. It also provides onshore students the opportunity to study with a partner University overseas. UOW upgraded from manual paper-based process to Appian's low-code development platform in the cloud. This allowed UOW to rapidly switch to online application submission and processing all within one app.

"The application process is the first interaction international students have with the University," said Fiona Rankin, CIO at the University of Wollongong. "It was important to us that during this first interaction we were presenting ourselves as modern and efficient, by making the application process completely online and as simple and fast as possible. With the support of Appian, we are now able to offer inbound international students one simple online platform in which they can quickly apply for and fully manage their study abroad or exchange program."

Within UOW's International On-line Student Mobility Application, inbound international students can complete online applications, submit course preferences, view student transcripts, receive notifications of actions such as faculty approvals, add new subjects, keep track of their study plan, and manage fees, payments and grants.

For UOW, the app has significantly enhanced the international student application process for its own staff too. Staff can now manage applications end-to-end online, which has streamlined and increased the speed in which they can accept and process applications.

"Appian is focused on helping Australian organisations, including a number of universities, to deliver on their digital transformation goals," said Karen Astley, Vice President Asia-Pacific, Appian. "Universities operate in an increasingly competitive global market and they must remain agile and adaptable to change. We empower customers like UOW to streamline their operations, maximise their resources and perform faster and more efficient than ever before."

UOW is an international institution, with campuses in Dubai and Hong Kong and links to educational institutions around the world. The University has formal agreements with more than 150 overseas institutions in the areas of research collaboration, student and staff exchange, study abroad and off-shore program delivery. Over 12,000 study abroad and exchange students have come from other universities to study at UOW.

For more information on Appian, click here.

Forward-Looking Statements

This press release includes forward-looking statements. All statements contained in this press release other than statements of historical facts, including, without limitation, the results obtained by customers using the Appian low-code software development platform, are forward-looking statements. The words "anticipate," believe," "continue," "estimate," "expect," "intend," "may," "will" and similar expressions are intended to identify forward-looking statements. Appian has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Appian believes may affect its financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. Those forward-looking statements are subject to a number of risks and uncertainties, including, without limitation, risks related to Appian's ability to meet its customers' needs by scaling its business sufficiently quickly, continuing to innovate and provide a useful platform, and providing satisfactory deployment services, and the risks and uncertainties set forth in the "Risk Factors" section of Appian's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission, and subsequent reports that Appian has filed with the Securities and Exchange Commission. Moreover, Appian operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for Appian's management to predict all risks, nor can Appian assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements Appian may make. In light of these risks, uncertainties and assumptions, Appian cannot guarantee future results, levels of activity, performance, achievements or events and circumstances reflected in the forward-looking statements will occur. Appian is under no duty to update any of these forward-looking statements after the date of this press release to conform these statements to actual results or revised expectations, except as required by law.

About Appian

Appian provides a leading low-code software development platform that enables organizations to rapidly develop powerful and unique applications. The applications created on Appian's platform help companies drive digital transformation and competitive differentiation. For more information, visit www.appian.com

For Information Contact:
Nicole Greggs
Director of Media Relations
+1 703-260-7868
nicole.greggs@appian.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Appian Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum